These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30067438)

  • 1. Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients.
    Omarini C; Bettelli S; Caprera C; Manfredini S; Caggia F; Guaitoli G; Moscetti L; Toss A; Cortesi L; Kaleci S; Maiorana A; Cascinu S; Conte PF; Piacentini F
    Cancer Biol Ther; 2018; 19(10):879-886. PubMed ID: 30067438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
    Pizzuti L; Krasniqi E; Barchiesi G; Della Giulia M; Izzo F; Sanguineti G; Marchetti P; Mazzotta M; Giusti R; Botticelli A; Gamucci T; Natoli C; Grassadonia A; Tinari N; Iezzi L; Tomao S; Tomao F; Tonini G; Santini D; Astone A; Michelotti A; De Angelis C; Mentuccia L; Vaccaro A; Magnolfi E; Gelibter A; Magri V; Cortesi E; D'Onofrio L; Cassano A; Rossi E; Cazzaniga M; Moscetti L; Omarini C; Piacentini F; Fabbri MA; Scinto AF; Corsi D; Carbognin L; Bria E; La Verde N; Samaritani R; Garufi C; Barni S; Mirabelli R; Sarmiento R; Veltri EM; D'Auria G; Paris I; Giotta F; Lorusso V; Cardillo F; Landucci E; Mauri M; Ficorella C; Roselli M; Adamo V; Ricciardi GRR; Russo A; Berardi R; Pistelli M; Fiorio E; Cannita K; Sini V; D'Ostilio N; Foglietta J; Greco F; Zamagni C; Garrone O; Di Cocco B; Baldini E; Livi L; Desideri I; Meattini I; Sarobba G; Del Medico P; De Tursi M; Generali D; De Maria R; Risi E; Ciliberto G; Sperduti I; Villa A; Barba M; Di Leo A; Vici P
    Int J Cancer; 2020 Apr; 146(7):1917-1929. PubMed ID: 31330065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.
    Omarini C; Bettelli S; Caprera C; Manfredini S; Barbolini M; Moscetti L; Isca C; Toss A; Barbieri E; Cortesi L; Kaleci S; Maiorana A; Tazzioli G; Cascinu S; Piacentini F
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):821-828. PubMed ID: 30603906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
    Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
    Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels.
    Sorokin M; Ignatev K; Barbara V; Vladimirova U; Muraveva A; Suntsova M; Gaifullin N; Vorotnikov I; Kamashev D; Bondarenko A; Baranova M; Poddubskaya E; Buzdin A
    Biochemistry (Mosc); 2020 Jul; 85(7):758-772. PubMed ID: 33040720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
    Murthy P; Kidwell KM; Schott AF; Merajver SD; Griggs JJ; Smerage JD; Van Poznak CH; Wicha MS; Hayes DF; Henry NL
    Breast Cancer Res Treat; 2016 Feb; 155(3):589-95. PubMed ID: 26875184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
    Sperinde J; Huang W; Vehtari A; Chenna A; Kellokumpu-Lehtinen PL; Winslow J; Bono P; Lie YS; Petropoulos CJ; Weidler J; Joensuu H
    Clin Cancer Res; 2018 Jul; 24(13):3046-3052. PubMed ID: 29535130
    [No Abstract]   [Full Text] [Related]  

  • 11. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
    Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting HER2 in Advanced Breast Cancer.
    Zhu X; Joy AA
    Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
    Eppenberger-Castori S; Klingbiel D; Ruhstaller T; Dietrich D; Rufle DA; Rothgiesser K; Pagani O; Thürlimann B
    BMC Cancer; 2020 Feb; 20(1):114. PubMed ID: 32046665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients.
    Hacioglu B; Akin S; Sever AR; Altundag K
    Future Oncol; 2015 Sep; 11(18):2495-7. PubMed ID: 26278702
    [No Abstract]   [Full Text] [Related]  

  • 17. Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003-2015).
    Daniels B; Kiely BE; Tang M; Tervonen H; Pearson SA
    BMC Cancer; 2019 Sep; 19(1):909. PubMed ID: 31510955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
    Schramm A; Friedl TW; Schochter F; Scholz C; de Gregorio N; Huober J; Rack B; Trapp E; Alunni-Fabbroni M; Müller V; Schneeweiss A; Pantel K; Meier-Stiegen F; Hartkopf A; Taran FA; Wallwiener D; Janni W; Fehm T
    Arch Gynecol Obstet; 2016 Feb; 293(2):271-81. PubMed ID: 26354331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.